Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Periprocedural bridging in VTE patients tied to greater bleeding incidence

10 Jul 2019

Compared with vitamin K antagonist (VKA) without bridging, periprocedural bridging is associated with a higher risk of bleeding, with no significant difference in periprocedural venous thromboembolism (VTE) rates, results of a systematic review have shown.

This study sought to examine recurrent VTE and bleeding outcomes with and without bridging in patients with previous VTE due to the uncertain benefits and risks of periprocedural bridging in this population.

The investigators searched the PubMed and Embase databases from inception to 7 December 2017 for randomized and nonrandomized studies that included adults with previous VTE requiring VKA interruption to undergo an elective procedure and that reported VTE or bleeding outcomes. Quality of evidence was graded by consensus.

Twenty-eight cohort studies (20 single-arm cohorts) with a total of 6,915 procedures were analysed. In 27 studies reporting perioperative VTE outcomes, recurrent VTE with bridging had a pooled incidence of 0.7 percent (95 percent CI, 0.4–1.2 percent), while that in recurrent VTE without bridging was 0.5 percent (0.3–0.8 percent).

In 18 studies, major or nonmajor bleeding outcomes were reported. The corresponding pooled incidence of any bleeding for with and without bridging was 3.9 percent (2.0–7.4 percent) and 0.4 percent (0.1–1.7 percent). The pooled incidence for VTE in bridged patients at high thromboembolic risk was 0.8 percent (0.3–2.5 percent) and 7.5 percent (3.1–17.4 percent) for any bleeding.

Due to a high risk of bias among included studies, the quality of available evidence was very low.

“VKA are the most widely used anticoagulants, and bridging is commonly administered during periprocedural VKA interruption,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.